GlassScriptPhysician profile
Pierre R Manzo
NPI 1033199468
$5,362.94
in general payments reported to CMS, 2019-2025
36 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $156 · 2021: $418 · 2022: $1,034 · 2023: $1,033 · 2024: $1,047 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,154.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $834.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $802.59 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $794.25 | 2019-2025 | |
| Pfizer INC. | $585.81 | 2019-2025 | |
| Amgen INC. | $308.18 | 2019-2025 | Repatha, Evenity, Otezla |
| Glaxosmithkline, LLC. | $292.84 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Merck Sharp & Dohme LLC | $179.41 | 2019-2025 | M-M-R II, Gardasil 9, Vaxelis |
| Exact Sciences Corporation | $177.94 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $130.66 | 2019-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $123.56 | 2022 | |
| Antares Pharma, INC. | $120.57 | 2024-2025 | Xyosted |
| Mayne Pharma Commercial LLC | $94.83 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $85.95 | 2019-2025 | Orencia, Eliquis |
| Abbott Laboratories | $85.59 | 2021-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $81.92 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $72.88 | 2021-2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $51.25 | 2021 | |
| Corium, LLC | $50.90 | 2023-2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $47.71 | 2021-2022 | |
| Ucb, INC. | $46.42 | 2019 | |
| Janssen Pharmaceuticals, INC | $44.88 | 2019 | |
| Mylan Specialty L.P. | $43.71 | 2019-2021 | |
| Amarin Pharma, INC. | $40.30 | 2021-2022 | |
| Dexcom, INC. | $37.98 | 2024-2025 | Dexcom G6 Transmitter |
| Abiomed | $33.78 | 2024 | Impella |
| Axsome Therapeutics, INC. | $28.70 | 2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $24.44 | 2019 | |
| Bausch Health US, LLC | $22.65 | 2022 | |
| Astellas Pharma US INC | $21.89 | 2021 | |
| Coopersurgical, INC. | $17.86 | 2024 | Paragard T 380a |
| Regeneron Healthcare Solutions, INC. | $17.15 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $16.26 | 2024 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.98 | 2020 | |
| Allergan, INC. | $13.25 | 2020 | |
| Echosens North America, INC. | $9.67 | 2025 | Fibroscan |
| Organon LLC | $6.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pierre Manzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.